<DOC>
	<DOC>NCT02103569</DOC>
	<brief_summary>The purpose of this study is to assess the effect of DCV/ASV/BMS-791325 fixed dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of the oral contraceptive agent.</brief_summary>
	<brief_title>Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325</brief_title>
	<detailed_description>IND Number: 79,599 and 101,943 Other: Phase 1 Clinical Pharmacology drug interaction study in healthy female subjects</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Norinyl</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Healthy females within age of 1840 years Must be a Women of Childbearing potential Must be on a stable regimen of oral contraceptive therapy for at least 3 consecutive months prior to study start Subjects must not have any significant acute or chronic medical illnesses or conditions precluding safe use of oral contraceptives Prior exposure to DCV, ASV or BMS791325 within 30 days of dosing on study day 1 Smoking within 6 months of study start</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>